Published November 6, 2025 | Version v1

COVID-19 AND DIABETES: MUTUAL INFLUENCE AND THERAPY CONSIDERATIONS

  • 1. IK Akhunbaev Kyrgyz State Medical Academy

Description

The combination of diabetes mellitus and COVID-19 infection represents one of the most significant clinical and social challenges in modern healthcare, posing a high risk of complications and mortality. This study aims to analyze the mutual influence of these diseases, focusing on their pathophysiological mechanisms, clinical features, and therapeutic approaches. Key interactions are examined, including activation of the renin-angiotensin-aldosterone system, endothelial dysfunction, carbohydrate and lipid metabolism disorders, and the cytokine cascade. Hyperglycemia has been shown to enhance inflammatory responses and oxidative stress, contribute to coagulopathy, and worsen the prognosis of COVID-19. The SARS-CoV-2 virus, in turn, can damage pancreatic β-cells and cause the development of new or decompensated diabetes. An analysis of clinical and experimental data highlights the need for an individualized approach, including strict glycemic control, thrombosis prevention, and inflammatory management. Particular attention is paid to the role of metformin, insulin, GLP-1 receptor agonists, and DPP-4 inhibitors in pathogenetically based therapy. The results underscore the importance of a multidisciplinary approach and the need for further research on the prevention and rehabilitation of patients with COVID-19 and diabetes.

Files

DIZZW #115_October_jornal-22-26.pdf

Files (372.4 kB)

Name Size
md5:c311fce07243256d263f2270a9db8119
372.4 kB Preview Download

Additional details

References

  • 1. Barron E., Bakhai C., Kar P. et al.Associa tions of type 1 and type 2 diabetes with COVID-19 related mortality in England // Lancet Diabetes & En docrinology. – 2020. – Vol. 8, No. 10. – P. 813–822. 2. Bornstein S.R., Rubino F., Khunti K. et al.Practical recommendations for the management of diabetes in patients with COVID-19 // Lancet Diabe tes & Endocrinology. – 2020. – Vol. 8, No. 6. – P. 546–550. 3. Cariou B., Hadjadj S., Wargny M. et al.Phenotypic characteristics and prognosis of inpa tients with COVID-19 and diabetes: the CORONADO study // Diabetologia. – 2020. – Vol. 63, No. 8. – P. 1500–1515.
  • 4. Ceriello A.Hyperglycemia and COVID-19: what was known and what is really new? // Diabetes Research and Clinical Practice. – 2020. – Vol. 167. – Article ID 108383. 5. Drucker DJThe potential role of D-1 recep tor agonists and DPP-4 inhibitors in COVID-19 // Dia betes. – 2020. – Vol. 46, No. 6. – P. 442–447. 6. Drucker DJCoronavirus infections and type 2 diabetes – shared pathways with therapeutic implica tions // Endocrine Reviews. – 2021. – Vol. 42, No. 3. – P. 367–397. 7. Gupta R., Hussain A., Misra A.Diabetes and COVID-19: evidence, current status and unan swered research questions // European Journal of Clin ical Nutrition. – 2020. – Vol. 74, No. 6. – P. 864–870. 8. Hoffmann M., Kleine-Weber H., Schroeder S. et al.SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clini cally proven protease inhibitor // Cell. – 2020. – Vol. 181, No. 2. – P. 271–280. 9. Muniyappa R., Gubbi S.COVID-19 pan demic, coronaviruses, and diabetes mellitus // Ameri can Journal of Physiology – Endocrinology and Me tabolism. – 2020. – Vol. 318, No. 5. – P. E736–E741. 10. Rubino F., Amiel SA, Zimmet P. et al.New onset diabetes in COVID-19 // New England Journal of Medicine. – 2020. – Vol. 383, No. 8. – P. 789–790. 11. Sathish T., Kapoor N., Cao Y. et al.Propor tion of newly diagnosed diabetes in COVID-19 pa tients: a systematic review and meta-analysis // Diabe tes, Obesity and Metabolism. – 2021. – Vol. 23, No. 3. – P. 870–874. 12. Singh AK, Gupta R., Ghosh A., Misra A.Diabetes in COVID-19: prevalence, pathophysiol ogy, prognosis and practical considerations // Diabetes & Metabolic Syndrome: Clinical Research & Re views. – 2020. – Vol. 14, No. 4. – P. 303–310. 13. Wu Z., McGoogan J.M.Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72,314 cases // JAMA. – 2020. – Vol. 323, No. 13. – P. 1239–1242. 14. Zhou W., Ye S., Wang W. et al.Clinical fea tures of COVID-19 patients with diabetes and second ary hyperglycemia // Journal of Diabetes Research. – 2021. – Vol. 2021. – Article ID 1–8.